Attorney Ahn Ju-hyun is a former physician who completed the Judicial Research and Training Institute's 39th class and previously worked at the Financial Supervisory Service, giving him a unique professional background as an expert in both the medical and financial sectors. At the firm, he actively demonstrates his expertise in matters involving regulatory supervision and inspections by financial authorities, financial regulatory matters such as licensing and approvals, financial disputes including recovery of distressed assets and damages litigation, as well as medical litigation and advisory work relating to pharmaceuticals and healthcare.
His major representations include:
• Advisory regarding Financial Supervisory Service inspections and sanctions imposed on financial institutions
• Litigation seeking revocation of monetary and personal sanctions arising from violations of financial regulatory laws, including the Capital Markets Act, the Insurance Business Act, the Mutual Savings Banks Act, and the External Audit Act
• Advisory relating to unfair trading practices such as insider trading by listed companies
• Advisory and litigation relating to recovery of distressed assets for financial institutions, including the KRW 200 billion Mitron fraud case
• Damages disputes involving matters such as the Global Healthcare Fund case
• Product liability litigation involving matters such as the humidifier disinfectant incident and textured breast implant litigation involving Allergan plc in the United States
• Civil and criminal medical malpractice cases involving patient deaths and hypoxic brain injuries
Attorney Ahn has advised or continues to advise public institutions including the Financial Supervisory Service, the Mutual Savings Banks Central Association, and the Korea Deposit Insurance Corporation. He also actively participates in external professional activities, including serving as a Financial Dispute Mediation Committee Member (Insurance Division, 2021–2023) at the Financial Supervisory Service and as a Management Evaluation Committee Member for specialized credit finance companies at the Financial Supervisory Service (2025–Present).